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Abstract
Background: Expansion of a polyglutamine repeat at the amino-terminus of huntingtin is the
probable cause for Huntington's disease, a lethal progressive autosomal-dominant
neurodegenerative disorders characterized by impaired motor performance and severe brain
atrophy. The expanded polyglutamine repeat changes the conformation of huntingtin and initiates
a range of pathogenic mechanisms in neurons including intracellular huntingtin aggregates,
transcriptional dysregulation, energy metabolism deficits, synaptic dystrophy and ultimately
neurodegeneration. It is unclear how these events relate to each other or if they can be reversed
by pharmacological intervention. Here, we describe neuronal cell lines expressing inducible
fragments of normal and mutant huntingtin.
Results:  In HN10 cells, the expression of wild type and mutant huntingtin fragments was
dependent on the induction time as well as on the concentration of the RheoSwitch® inducing
ligand. In order to analyze the effect of mutant huntingtin expression on cellular functions we
concentrated on the 72Q exon1 huntingtin expressing cell line and found that upon induction, it
was possible to carefully dissect mutant huntingtin-induced phenotypes as they developed over
time. Dysregulation of transcription as a result of mutant huntingtin expression showed a
transcription signature replicating that reported in animal models and Huntington's disease
patients. Crucially, triggering of neuronal differentiation in mutant huntingtin expressing cell
resulted in the appearance of additional pathological hallmarks of Huntington's disease including cell
death.
Conclusion: We developed neuronal cell lines with inducible expression of wild type and mutant
huntingtin. These new cell lines represent a reliable in vitro system for modeling Huntington's
disease and should find wide use for high-throughput screening application and for investigating the
biology of mutant huntingtin.
Background
Huntington's disease (HD) is an inherited, autosomal-
dominant neurodegenerative disorder whose main clini-
cal symptoms include chorea, cognitive decline and
weight loss [1]. Disease onset occurs normally at mid-age
followed by a relentless disease progression and prema-
ture death 10 to 20 years after appearance of clinical
symptoms [2]. HD is caused by a mutated and expanded
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CAG repeat in the huntingtin gene (htt) resulting in an
elongated polyglutamine (polyQ) stretch in the mutant
huntingtin protein (Htt) [3].
Proteolytic cleavage of full-length mutated Htt could rep-
resent the pathogenic rate-limiting step [4] which pro-
duces aggregation-prone amino-terminal Htt fragments
carrying the expanded polyQ repeat [5]. These fragments
are toxic in vitro and in vivo through a gain of function
mechanism but the causes for neuronal dysfunction initi-
ated by mutant Htt are not fully understood [6,7]. Mutant
Htt toxicity correlates with the length of the polyQ repeat
and the amount of mutant Htt fragments accumulating in
the cells, whereby shorter Htt fragments are more patho-
genic than longer fragments or full-length Htt [5,8-11].
Different pathogenic mechanisms are discussed, includ-
ing dysregulation of transcription [12], abnormalities in
the ubiquitin/proteasome system [13], impaired axonal
trafficking, microtubule destabilization [14,15] and mito-
chondrial dysfunction [16]. One of the earliest events is
the typical transcription dysregulation signature displayed
in cellular and animal HD models of the disorders as well
as in the HD brain [12]. Transcription factors such as spe-
cificity protein 1 (SP1) [17] and cAMP response element
binding protein (CREB) [18] interact with mutant Htt and
are sequestered into aggregates, resulting in transcription
abnormalities of their target genes.
Cellular models of HD are essential for studying the biol-
ogy of mutant Htt. Non-neuronal primary cells from HD
patients have been used to study CAG-repeat instability
[19] or calcium homeostasis [20]. PC12-cell based models
of Htt toxicity have been used for drug screens [21].
Mutant Htt leads to neurite degeneration and induction of
apoptosis in murine primary neuronal cultures [22,23].
Immortalized striatal neurons showed increased vulnera-
bility to mitochondrial toxins and impaired mitochon-
drial complex II function in presence of stable mutant Htt
expression [24,25]. Such models based on primary neu-
rons cultures or Htt expressing cell lines greatly improved
our understanding of HD pathogenesis. Nevertheless,
they also present some drawbacks for use in drug discov-
ery such as the limited use of primary neuronal cultures
for high-throughput screening or the adaptive changes
expected in cells chronically exposed to stably expressed
mutant Htt. We opted to address some of these aspects by
generating inducible HN10 neuronal lines. HN10 cells
resist several treatments such as cDNA transfection and
compound treatment and can be easily differentiated into
neuron-like post-mitotic cells [26,27]. Upon induction of
Htt expression and differentiation into post-mitotic neu-
rons, HN10 cells develop a number of HD-like pheno-
types. Our cell lines can be used for chemical and genetic
high-throughput screenings, represent models for dissect-
ing the mechanism of action of drug candidates and allow
for assessing the role of novel targets in neuroprotection.
Materials and methods
HN10 cells culturing conditions
Dividing HN10 cells were propagated in proliferating cul-
ture medium: high-glucose DMEM (Invitrogen #31966-
021), 10% fetal calf serum, penicillin, geneticin, hygromy-
cin and streptomycin and maintained at 37°C in 5% CO2.
Medium replacement and passaging of the cells occurred
every 2–3 days. In order to induce cell differentiation, pro-
liferating cells were harvested, resuspended in proliferat-
ing culture medium and plated at 20% confluency on
dishes pre-coated with 20 μg/μl laminin (SIGMA
#L2020). The cells were then cultured one day later in dif-
ferentiating medium: serum-free high-glucose DMEM,
neuronal supplements [28] and 45 μM retinoic acid
(SIGMA #R2625) for up to 7 days.
Production of stable inducible cell clones
HN10 cells were transfected with the RheoReceptor
pNEBR-R1 plasmid (RheoSwitch Mammalian Inducible
Expression System, New England Biolabs) using Lipo-
fectamine™ 2000 (Invitrogen #11668-019). Transfected
cells were counted and seeded in 96-well plates. Dilution
series were made in a way to obtain single clones in the
wells with the highest cell dilutions. Transfected cells were
selected using 1 mg/ml Geneticin (Invitrogen #10131-
027). After 2 weeks of selection, more than 30 clones were
harvested and further expanded in a 24-well plate. Twenty
one clones were selected based on similarity to the paren-
tal HN10 cell line in terms of morphology, growth rate
and ability to differentiate. Successful integration of the
RheoReceptor was confirmed by transient transfection
with the reporter plasmid pNEBR-X1 expressing Gaussia
luciferase and treatment for two days in the presence of
500 nM RSL1 inducer. The receptor-clone #14, which dis-
played the best luciferase induction ratio and no basal
expression, was selected for production of Htt inducible
cell lines expressing the amino-terminal Htt fragments
25Q Htt-exon1 (cell line Exon1-Q25-S), 72Q Htt-exon1
(Exon1-Q72-V), 25Q Htt-857 (aa857-Q25-B) and 72Q
Htt-857 (aa857-Q72-B) subcloned in the pNEBR-
X1Hygro plasmid.
Subcellular fractionation
The HN10 cell line Exon1-Q72-V was cultured in the pres-
ence or absence of 500 nM RSL1 for two days. Cells were
then washed with PBS and nuclear and cytosolic fractions
were obtained as described [29]. Purity of the nuclear and
cytosolic fractions was verified by western blot using an
antibody against a protein marker for the cytoplasma
(tubulin; abcam antibody #ab28037-100; dilution
1:4000) or for the nucleus (histone H3; Chemicon anti-
body #MAB052; 1:2000).Molecular Neurodegeneration 2009, 4:11 http://www.molecularneurodegeneration.com/content/4/1/11
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Immunostaining
HN10 cells were fixed in 4% formaldehyde and stained
with 1:500 anti-Htt antibody 2B7 (custom production by
NanoTools, Freiburg, Germany), 1:100 anti-Htt mEM48
antibody (Millipore, MAB 5374) or 1:1000 anti-poly-
glutamine antibody m1C2 (Millipore, MAB 1574). Cell
nuclei were visualized with 1:20000 Hoechst nuclear stain
(Invitrogen #33258). Standard immunohistochemistry
protocols and fluorescence microscopy were used.
Western Blot and AGERA
Soluble and aggregated mutant Htt fragments were deter-
mined by western blot or AGERA as described [11].
Real-time PCR
The HN10 clone 72Q Htt-exon1 was cultured under pro-
liferating or differentiating conditions with or without
induction of Htt expression in a 24 well plate (Becton
Dickinson #353047). Total RNA was isolated with the
RNeasy Mini Kit (Qiagen). Real-time PCR was performed
using customized TaqMan®  microfluidic card arrays
(Applied Biosystems) according to the manufacturer pro-
tocol. Eight different samples were analyzed simultane-
ously against 15 probes and one 18S normalization
control probe. First-Strand cDNA synthesis was done with
100 to 150 ng RNA according to the manufacturer proto-
col (Invitrogen, SuperScript III Platinum #11732-088).
PCR amplifications in the microfluidic card were per-
formed using a solution made of 30 μl cDNA, 50 μl 2×
Platinum qPCR SuperMix-UDG with ROX (Invitrogen
#11744-500) and 100 μl DEPC water. After two centrifu-
gations of 1000 g for 1 min, microfluidic cards were sealed
and analyzed after an incubation at 50°C for 2 min and at
94.5°C for 2 min. Amplification parameters corre-
sponded to 45 cycles at 97°C for 30 sec and 59.7°C for 1
min. Ct values were normalized against the 18S calibra-
tion control.
Protein determination and aconitase measurements
For protein and aconitase measurements, HN10 cells were
cultured on 24-well plates (Becton Dickinson #353047)
with a starting plating density of 34 000 cells/well. After 1,
2 and 3 days of cell culture, cells were washed three times
with PBS and protein content in each well was measured
with the BCA™ Protein Assay Kit (Perbio, #23227). The
aconitase activity assay was adapted from published
methods [30,31]. Briefly, cells were washed with 100 μl/
well PBS followed by addition of 100 μl/well aconitase
buffer: 30 mM sodium citrate, 0.5 mM MnCl2, 0.2 mM
NADP, 2 U/ml isocitrate dehydrogenase, 1% Triton in 50
mM Tris adjusted to pH 7.5. Kinetic measurements over
the first 30 min were done at 37°C using a Fluoroskan
(Thermo Scientific, Fluoroskan Ascent FL) with excitation
at 355 nm and emission at 460 nm. Aconitase activity was
determined by linear regression of the linear part of the
curve.
Caspase 3/7 activity
HN10 cells were cultured under differentiating conditions
with or without inducer for up to 5 days on opaque 96-
well plates (Becton Dickinson #353296). Total caspase 3/
7 activity per well was determined using the caspase-Glo
3/7 Assay (Promega, #G8091) as recommended by the
manufacturer using a RUBYstar Reader (BMG Labtech).
Neurite quantification
Analysis of the neurite network was performed with a LI-
COR Biosciences In-Cell Western™ assay. HN10 cells were
cultured under differentiating conditions for up to 6 days
on clear bottom 96-well plates (Becton Dickinson
#353072). During this incubation time, HN10 cells
formed an extensive neurite network. After fixation with
4% paraformaldehyde, neurites were immunostained
with an anti-α-tubulin antibody (1:1000, abcam,
#ab28037-100) and IRDye 800CW secondary antibody
(LI-COR Biosciences). Total amount per well of tubulin
was determined with an Odyssey Imager (LI-COR Bio-
sciences) and normalized against number of nuclei
(DRAQ5™, Biostatus Limited).
Results
Inducible expression of Htt in the neuronal HN10 cell lines
In vitro models facilitate the dissection of Htt toxicity.
Optimally, these cellular models will recapitulate HD-like
pathological hallmarks. We generated four stable neuro-
nal HN10 clone lines with inducible expression of short
(Htt-exon1) or long (Htt-857) amino-terminal Htt frag-
ments carrying either normal (25Q) or mutant (72Q)
polyQ lengths (Fig. 1A). All cell lines displayed no basal
expression of the fragments, whereas inducible Htt expres-
sion was demonstrated by western blot analysis of cell
lysates (Fig. 1B) and immunohistochemistry, whereby a
subset of 72Q Htt-exon1 cells formed cellular aggregates
within few days after induction (Fig. 1C).
Htt fragments were first detected 6 h upon induction and
reached maximal expression at 24 h (Fig. 2A). Removal of
the inducer from the culture medium caused a time-
dependent disappearance of the Htt fragments (Fig. 2B)
demonstrating expression reversibility and rapid Htt deg-
radation. Quantification of Htt by western blot revealed
dose-dependent increase in expression as a function of the
amount of inducer (Fig. 2C). Supporting the immunohis-
tochemical observation, aggregate formation in the 72Q
Htt-exon1 cells was confirmed by AGERA (Fig. 2D). No
detectable aggregates were found in cells expressing 72Q
Htt-857, 25Q Htt-857 or 25Q Htt-exon1 fragments (data
not shown).Molecular Neurodegeneration 2009, 4:11 http://www.molecularneurodegeneration.com/content/4/1/11
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In cellular and animal models of HD mutant huntingtin
normally accumulates in nuclear aggregates [23,32] lead-
ing to transcription abnormalities. To assess the intracel-
lular distribution 72Q Htt-exon1 protein in HN10 cells,
we isolated the nuclei of HN10 cells. The purity of the
nuclear fraction was demonstrated by Western blot using
histone H3 as a protein marker for the nucleus and the
cytoplasmic marker tubulin (Fig. 2E). Using this protocol,
we demonstrated distribution of the soluble pool of
mutant Htt in both the cytoplasmic and the nuclear frac-
tion, whereby mutant Htt appeared predominantly local-
ized in the cytoplasma. In contrast, mutant huntingtin
aggregates accumulated exclusively in the nuclei of HN10
cells after two days of induction (Fig. 2E).
All subsequent experiments were aimed at characterizing
the 72Q Htt-exon1 cell line as it expresses a short amino-
terminal Htt fragment, which is expected to display prom-
inent toxicity. Importantly, mutant Htt-dependent
impairment of cell viability is most pronounced in post-
mitotic neurons [32-35]. In order to differentiate HN10
cells, we applied culturing conditions optimized for pri-
mary neurons that indeed induced rapidly a neuron-like
morphology (Fig. 3). Under these conditions, differenti-
ated HN10 cells displayed neuronal properties [26].
Mutant Htt causes transcription abnormalities
We examined the consequence of mutant Htt induction
on transcription dysregulation of representative genes that
exhibit SP1 or CREB control elements in their respective
promoters.
First, actively dividing HN10 cells expressing 72Q Htt-
exon1 where compared to non-induced cells. Among the
15 mRNA analyzed, four genes showed a significant
down-regulation of transcription in the presence of
mutant Htt (caspase 8, HSP27, PGC-1α and TFAM; Fig.
4A). The strongest effect was found for the peroxisome
proliferator-activated receptor-gamma coactivator 1α
(PGC-1α), a CREB and Sp1 dependent master regulator of
mitochondriogenesis and of the reactive oxygen protec-
tive pathway [36]. A difference in PGC-1α expression is a
critical feature of a cell model of the disorder as it has been
reported to be robustly down-regulated in medium spiny
neurons in HD [37,38]. Caspase 8 and the heat shock pro-
tein HSP27 are under the control of the Sp1 element,
whereas the mitochondrial transcription factor TFAM is
under the control of CREB. Another prominent hallmark
gene in the transcription signature of HD is the dopamine
receptor DRD2, whose expression was not detected in the
hippocampal HN10 cells. The fact that only a subset of
genes was affected may highlight early and possibly more
relevant transcription abnormalities occurring in cells
after exposure to mutant Htt.
In differentiated HN10 cells, induction of 72Q Htt-exon1
expression was also accompanied by transcription dysreg-
ulation of four genes (Fig. 4B), whereby two genes were
down-regulated (PGC-1α and the adenosine A2a receptor
ADORA2a) and two genes were up-regulated (MSX1 and
PRKCB1) when compared to cells lacking mutant Htt.
Abnormalities in ADORA2a were reported to be associ-
ated with HD [39,40]. Msh-like 1 (MSX1) homeobox has
Inducible expression of wild-type and mutant huntingtin fragments in clonal HN10 cell lines Figure 1
Inducible expression of wild-type and mutant huntingtin fragments in clonal HN10 cell lines. A: Scheme of nor-
mal (25Q) and mutant (72Q) Htt fragments used for creation of inducible HN10 cell lines. B: Induction of Htt expression with 
500 nM RheoSwitch® Ligand (RSL1) normalized for tubulin content in cell lysates demonstrated by western blot analysis. No 
basal expression is detected in non-induced cells. C: Expression of induced Htt shown by fluorescent immunocytochemistry of 
Htt cell lines treated in the presence or absence of inducer. Five days of induction with 500 nM RSL1 results in the appearance 
of Htt inclusions specifically in a subset of 72Q Htt-exon1 cells (white arrows).
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been reported to represent a candidate modifier of HD
age-of-onset [41], whereas protein kinase C β1 (PRKCB1)
has been shown to be dysregulated in HD [42]. Transcrip-
tion dysregulation was more prominent in differentiated
HN10 cells than in proliferating cells, possibly because of
increased Htt accumulation in post-mitotic cells or
because neurons are more susceptible to mutant Htt tox-
icity.
Mutant Htt expression caused transcription dysregulation
of different subsets of genes (with the exception of PGC-
1α) when comparing proliferating and differentiated
HN10 cells. This apparent discrepancy may result from
differentiation-dependent changes in overall gene tran-
scription. To explore this possibility in more details, we
compared gene expression in proliferating versus differen-
tiated HN10 in the absence of mutant Htt (Fig. 4C). Not
surprisingly, cell differentiation had indeed significant
effects on gene transcription with caspase 8, heat-shock
factor 1 (HSF1), PGC-1α and NAD(+)-dependent isoci-
trate dehydrogenase subunit 3 (IDH3) being significantly
changed upon differentiation. Up-regulation of PGC-1α
may reflect the increased energetic demand of neuronal
cells due to extensive neurite formation and for maintain-
ing the membrane potential.
Mutant Htt expression induces mitochondrial 
abnormalities and impairs cell viability
Dysregulation of PGC-1α and TFAM mRNA levels were
indicative of possible abnormalities in mitochondrial
function. Using aconitase activity as a marker for mito-
chondrial oxidative damage [31,43,44], we examined the
influence of 72Q Htt-exon1 expression on aconitase activ-
ity in proliferating or differentiated HN10 cells. Three
days after induction of mutant Htt expression, we found a
significant mitochondrial impairment in differentiated
cells (Fig. 5B) but not in proliferating cells (Fig. 5A) when
compared to non-induced control HN10 cells.
Regulated expression of 72Q Htt-exon1 and aggregation formation Figure 2
Regulated expression of 72Q Htt-exon1 and aggregation formation. A: Addition of 500 nM RSL1 inducer to the cul-
ture medium leads to a time dependent increase in 72Q Htt-exon1 expression first detectable after 6 h of treatment (western 
blot of biological triplicates). B: Time-dependent disappearance of 72Q Htt-exon1 in HN10 cells upon removal of the RSL1 
inducer from the culture medium. C: Dose dependent Htt expression as a function of RSL1 concentration in the culture 
medium of 25Q Htt-exon1, 72Q Htt-exon1, 25Q Htt-857 and 72Q Htt-857 cell lines (western blot quantification). D: AGERA 
blot of 72Q Htt-exon1 cell lysates reveals significant accumulation of Htt aggregates after induction of Htt expression but not 
in non-induced cells. E: Subcellular fractionation of cytoplasma and nuclei demonstrate the presence of abundant amounts of 
soluble Htt in the cytoplasma of the HN10 cells. In contrast, a minor pool of soluble mutant Htt and all aggregated 72Q Htt-
exon1 were detected in the nuclei.
 " 
	


 !&  
	!
"

!


# ' (
 

 # # 	

 	





!)
)!

*




+
+





  
 

$%	
+

!)!
! !! !! !! !! !!










 

,

,
+
! !! !! !! !! !!






-

,Molecular Neurodegeneration 2009, 4:11 http://www.molecularneurodegeneration.com/content/4/1/11
Page 6 of 12
(page number not for citation purposes)
Mitochondrial dysfunction may lead to apoptosis. Meas-
uring caspase 3/7 induction as a proapoptotic marker of
compromised cell viability, we observed increased caspase
3/7 activity in differentiated HN10 cells in the presence of
72Q Htt-exon1 (Fig. 5C) and 72Q Htt-857 (data not
shown). To confirm that the effects are a direct result of
the elongated polyQ stretch, we analyzed the conse-
quence of wild-type Htt. In contrast to the effects observed
upon induction of 72Q Htt-exon1, the expression of 25Q
Htt-exon1 resulted in decreased caspase 3/7 activity, con-
firming the neuroprotective properties reported for wild-
type Htt (Fig. 5C) [45].
Neurodegenerative properties of mutant Htt in HN10 cells
Upon differentiation, HN10 cells form a dense network of
processes (see above). It is possible to determine automat-
ically the extent of neurite outgrowth by measuring the
total amount of tubulin in each well. Normalization to
cell number was achieved by staining the cell nuclei and
thus the extent of the neurite network is reported as the
ratio of neurites (tubulin) per cell (nuclei) for each culture
conditions. When compared to non-induced HN10 cells,
72Q Htt-exon1 expressing cells showed a significant
decrease in the neurite network. Again, induction of 25Q
Htt-exon1 showed a protective effect, since wild-type Htt
expression resulted in more tubulin positive neurites per
cell nuclei (Fig. 6A). In contrast, induced expression of
72Q Htt-857 had no significant influence on the neurite
network (data not shown).
As a generic readout for cell viability, changes in total cel-
lular protein upon 72Q Htt-exon1 expression were deter-
mined. Cellular protein content increased with time when
culturing the cells under proliferating conditions, reflect-
ing the mitotic nature of the cells. A small but not signifi-
cant decrease in cellular protein levels was detected in the
proliferating clones after 3 days expression of 72Q Htt-
exon1 compared to proliferating non-induced clones (Fig.
6B). Toxicity of 72Q Htt-exon1 became more prominent
when keeping the clone under differentiating, post-
mitotic conditions (Fig. 6C). Here, significant decrease of
cellular protein levels between non-induced and induced
cells were detected already after two days of 72Q Htt-
exon1 expression and this effect became more pro-
nounced after 3 days of induction, indicating a general
impairment of cell viability as a result of mutant Htt
expression in differentiated cells.
Discussion
In order to establish a cellular model that can be used for
drug discovery and ultimately to elucidate some of the
pathogenic mechanisms leading to HD, we developed a
flexible neuronal cell line system where expression level
and exposure time of mutant Htt can be accurately con-
trolled.
In HN10 cells, mutant Htt toxicity was most evident when
the cells became post-mitotic. The ability to culture the
cells under proliferating as well as differentiating condi-
HN10 cells grown under proliferating and differentiated conditions Figure 3
HN10 cells grown under proliferating and differentiated conditions. Adjusting the culture conditions results in differ-
entiation of HN10 cells in a characteristic neuronal morphology. Representative phase-contrast micrographs and a fluorescent 
image of HN10 cells after immunocytochemistry staining with a tubulin-specific antibody (red channel) and Hoechst nuclear 
marker (blue channel). A dense neurite network is visible at 7 days of HN10 cell differentiation (bar = 100 μm).
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Transcriptional abnormalities in proliferating and differentiated HN10 cells in the presence or absence of mutant huntingtin Figure 4
Transcriptional abnormalities in proliferating and differentiated HN10 cells in the presence or absence of 
mutant huntingtin. A: mRNA determinations by real-time PCR of a selected panel of genes in mutant 72Q Htt-exon1 
expressing and control proliferating HN10 cells. B: Same as in A using differentiated, non-dividing HN10 cells. C: Effect of dif-
ferentiation of HN10 cells on transcription of the same genes. All graphs: n = 3, * p < 0.05*, ** p < 0.01, *** p < 0.001.
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Impaired aconitase activity and increased caspase 3 activation resulting from 72Q Htt-exon1 expression in differentiated cells Figure 5
Impaired aconitase activity and increased caspase 3 activation resulting from 72Q Htt-exon1 expression in dif-
ferentiated cells. Aconitase activity determination in cell lysates one and two days after induction of mutant Htt expression 
with 500 nM RSL1 in proliferating (A) and differentiated (B) 72Q Htt-exon1 cells (white bars) compared to non-expressing 
cells (black bars). C: Increase in caspase 3/7 activity in cell lysates after induction of 72Q Htt-exon1 expression with 500 nM 
RSL1 in differentiated HN10 cells (white bars). Expression of the wild-type 25Q Htt-exon1 decreases caspase 3/7 activity 
(black bars). All graphs: n = 3, * p < 0.05, ** p < 0.01.
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Toxic effect of mutant huntingtin expression in differentiated cells Figure 6
Toxic effect of mutant huntingtin expression in differentiated cells. A: Quantification of neurite extension as a func-
tion of cell number using InCell Western determination of tubulin versus nuclear ratios in differentiated HN10 lines one and 
two days after induction of wild-type (black bars) and mutant (white bars) Htt-exon1 with 500 nM RSL1. B, C: Total cell pro-
tein determinations in the presence or absence of 72Q Htt-exon1 expression in proliferating (B) or differentiated (C) HN10 
cells. All graphs: n = 3, * p < 0.05, ** p < 0.01.
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tions is relevant considering that terminally differentiated
cells such as neurons and myotubes display the strongest
aggregate formation and are most vulnerable to mutant
Htt expression [34,35,46-48]. Since the amount of mutant
Htt directly impinge on its toxicity [49], when cell division
is stopped, intracellular Htt may surpass the threshold
concentration required to initiate a cascade of toxic events
ultimately compromising neuronal activity and survival.
This may explain the results obtained when comparing
dividing and non-dividing HN10 cells. Firstly, we demon-
strated accumulation of mutant Htt leading to significant
load of intranuclear inclusions. Then, we identified early
abnormalities changes in transcription in differentiated
and dividing HN10 cells. Finally, we show clear Htt toxic-
ity phenotypes in post-mitotic cells such as aconitase
impairment, caspase 3 activation, neurite loss and
reduced total cell protein indicating an ongoing neurode-
generative process. Further studies are required to identify
and address in more details the specific cellular pathways
involved in Htt toxicity.
By comparing the effects of 25Q Htt-exon1 and 72Q Htt-
exon1 expression on cell viability, we showed that the sen-
sitivity of differentiated HN10 cells to mutated Htt is spe-
cific to the elongated polyglutamine stretch in the Htt
fragment and not a cause of ectopic expression of a short
Htt fragment. Interestingly, the expression of wild-type
Htt resulted in a protective effect on caspase 3 activity, a
finding which is in agreement with earlier in vitro and in
vivo evidence assigning a neuroprotective role to normal
Htt [45,50,51]. The use of an unmodified Htt fragment
instead of Htt fusion proteins broadly used in previous
investigations may highlight more disease-relevant phe-
notypes. Similarly, conditional Htt expression may reduce
the risk of possible clonal artifacts, which are often
encountered when comparing different clones generated
from the same parental cell line.
While the expression of amino-terminal mutated frag-
ments is known to lead to increased Htt toxicity, our
model prevents dissecting the cellular pathways regulat-
ing proteolytic processing of full-length Htt. In addition,
it is not excluded that additional pathogenic mechanisms
are initiated by more carboxy-terminal regions of the
mutated Htt protein. As an example, the nuclear export
signal present at the carboxy-terminus of Htt has been
implicated in Htt toxicity [52]. Hence, further develop-
ments of our models will include the generation of induc-
ible full-length Htt cell lines.
Conclusion
In summary, our HN10 cell-based neuronal model dis-
played several disease-relevant features typical of HD,
such as Htt aggregation, the characteristic transcriptional
abnormalities, decreased cell viability, impaired mito-
chondrial function and neurodegeneration [53]. Because
of the possibility to dissect these features in a time-
dependent as well as huntingtin expression level-depend-
ent manner, these cell lines represent a viable HD in vitro
model for drug discovery.
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